Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter And Nine Months Period Ended 31St December, 2020

ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/01/2021 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Tuesday, 19th January, 2021, inter-alia to consider and approve Unaudited Financial Results of the Company for the quarter and nine months period ended 31st December, 2020. Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st January, 2021, will re-open 48 hours after the declaration of the financial results. We request you to kindly take the same on record.
07-01-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended December 2020

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0550 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer
07-01-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2020, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record.
07-01-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Closure of Trading Window

With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st January, 2021 till 48 hours after the declaration of the unaudited financial results for the quarter and nine months period ended 31st December, 2020. The date of the Board Meeting for considering the unaudited financial results for the quarter and nine months period ended 31st December, 2020 will be intimated in due course. We request you to kindly take the same on record.
31-12-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificate(s) published by the Company on behalf of the registered shareholder(s) in English language newspaper - Business Standard on 25th December, 2020. We request you to kindly take the same on record.
25-12-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the following registered shareholder(s) on 16th December, 2020. We enclose herewith an intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.
16-12-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s) for the purpose of claiming those shares from the Investor Education and Protection Fund (IEPF). We enclose herewith a letter received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.
16-12-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Asenapine Sublingual Tablets, 5 mg and 10 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
11-12-2020
Bigul

Alembic Pharma gets USFDA nod for pills to treat salt, water retention

Alembic Pharmaceuticals said it received approval from the US health regulator for Metolazone tablets, indicated for the treatment of salt and water retention caused by heart failure or kidney disease
03-12-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Metolazone Tablets USP 2.5 mg, 5 mg, and 10 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
03-12-2020
Next Page
Close

Let's Open Free Demat Account